MohammedAsmalMD

Venture Partner, OrbiMed Advisers

Dr. Asmal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2006 - 2008
Brigham and Women's HospitalResidency, Internal Medicine, 2003 - 2006
Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

PubMed

26 citations
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
Julie Kanter, Alexis A Thompson, Francis J Pierciey Jr, Matthew Hsieh, Naoya Uchida
American Journal of Hematology. 2023-01-01
127 citations
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
Julie Kanter, Mark C Walters, Lakshmanan Krishnamurti, Markus Y Mapara, Janet L Kwiatkowski
The New England Journal of Medicine. 2022-02-17
78 citations
Betibeglogene Autotemcel Gene Therapy for Non-β/βGenotype β-Thalassemia.
Franco Locatelli, Alexis A Thompson, Janet L Kwiatkowski, John B Porter, Adrian J Thrasher
The New England Journal of Medicine. 2022-02-03

Abstracts/Posters

The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy
Mohammed Asmal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar Hgb-204 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 PatientsAugust 26th, 2020
Bluebird Bio Announces Topics for Gene Therapy Day, October Investor PresentationOctober 6th, 2016